Artera’s prostate biopsy and breast most cancers exams obtain a CE mark
Artera has obtained CE Mark approval below the European In Vitro Diagnostic Regulation (EU IVDR) for its ArteraAI prostate biopsy and breast most cancers exams, increasing the corporate’s international attain.
The ArteraAI prostate biopsy take a look at is alleged to be the primary AI-based prognostic and predictive in vitro diagnostic take a look at for prostate most cancers to be granted the CE mark.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
It predicts the chance of prostate most cancers development and related mortality, and assesses whether or not sufferers might profit from the addition of short-term hormone remedy (ST ADT) to their remedy plan.
The event follows Artera’s receipt of de novo authorization from the U.S. Meals and Drug Administration (FDA) for its ArteraAI prostate biopsy take a look at, marking the primary AI-powered software program for predicting long-term outcomes in non-metastatic prostate most cancers sufferers.
Each exams use digitized histopathology photos and scientific variables to find out most cancers aggressiveness and potential remedy responses, supporting extra personalised care.
They underwent analysis for high quality, total security and efficiency, together with a complete evaluation of scientific proof. This helps Artera’s willingness to commercially deploy its merchandise for varied most cancers indications on a worldwide scale.
Artera CEO and co-founder Andre Esteva stated: “Attaining CE Mark for our prostate and breast most cancers exams is a important milestone for Artera and underlines the scalability of our multimodal AI (MMAI) platform.
“Validating our AI-driven method below one of many world’s most rigorous regulatory frameworks marks an essential step in our international dedication and furthers our mission to deliver AI-powered choice making to precision oncology.”
The CE marking permits scientific use in all EU Member States and EFTA [European Free Trade Association] nations that collectively serve 450 million folks. Artera collaborates with European pathology laboratories and healthcare companions for native entry and orders.
The ArteraAI breast most cancers take a look at makes use of Artera’s MMAI platform, clinically validated in international cohorts and introduced at scientific occasions together with the San Antonio Breast Most cancers Symposium.
